Fentanyl
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Fentanyl: From Opioid Analgesia to Nephrogenic Syndrome of Inappropriate Antidiuresis
One-Sentence Summary
Fentanyl is a potent synthetic opioid analgesic, well established for the management of severe acute and chronic pain and as an anaesthetic adjunct. The TxGNN model predicts it may be effective for nephrogenic syndrome of inappropriate antidiuresis (NSIAD), but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-score-only signal with no corroborating evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved-indication text on file (evidence pack contains no ARTG/TFDA licence records for Fentanyl) |
| Predicted New Indication | Nephrogenic syndrome of inappropriate antidiuresis |
| TxGNN Prediction Score | 99.46% |
| Evidence Level | L5 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data was not available in this evidence pack (flagged as a High-severity data gap). Based on well-established pharmacology, Fentanyl is a potent mu-opioid receptor agonist used systemically for analgesia and anaesthesia.
NSIAD is a distinct condition caused by gain-of-function mutations in the vasopressin V2 receptor (AVPR2), leading to constitutive water reabsorption independent of vasopressin levels. There is no established pharmacological link between mu-opioid receptor agonism and AVPR2-mediated antidiuresis, and the evidence pack’s own mechanistic assessment concurs: this prediction reflects a knowledge-graph score with no biological plausibility support currently identified.
On balance, this candidate should be treated as a hypothesis-generating signal only, not a mechanistically grounded repurposing lead.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Australia Market Information
No ARTG entries found for Fentanyl in the current dataset (0 licences on record); market status is recorded as Not Marketed.
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN prediction score, there are zero clinical trials or publications supporting Fentanyl for NSIAD, and no plausible mechanistic overlap between opioid receptor pharmacology and AVPR2-mediated antidiuresis has been identified. This is an L5 (model-prediction-only) candidate at decision stage S0.
To proceed, the following is needed:
- TFDA/TGA-approved Product Information — warnings and contraindications (currently a Blocking data gap)
- Confirmed mechanism of action data from DrugBank (currently a High-severity data gap)
- Preclinical or mechanistic evidence establishing biological plausibility for a Fentanyl–NSIAD link before any further evaluation stage is warranted
- Confirmed original approved-indication text and Australian market/ARTG status for this drug
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.